Trials / Completed
CompletedNCT00134498
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
Detailed description
For additional information please call: 1-800-718-1021
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | torcetrapib/atorvastatin | |
| DRUG | atorvastatin |
Timeline
- Start date
- 2005-02-01
- Completion
- 2006-11-01
- First posted
- 2005-08-24
- Last updated
- 2007-11-16
Locations
44 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00134498. Inclusion in this directory is not an endorsement.